3SBio, a Chinese partner of Pfizer, plans to raise approximately $400 million through a share placement, primarily for research and development. This follows a previous agreement in July where Pfizer invested $100 million in 3SBio, aiming to advance cancer medicines. The collaboration highlights continued U.S.-China ties in healthcare despite broader trade tensions, with 3SBio's shares soaring over 300% in the past year.

三生制药

<p>3SBio，辉瑞的中国合作伙伴，计划通过配股筹集约 4 亿美元，主要用于研发。这是在 7 月份辉瑞投资 1 亿美元于 3SBio 以推动癌症药物研发的协议之后的举措。这一合作突显了尽管存在更广泛的贸易紧张局势，美中在医疗保健领域的持续联系，3SBio 的股价在过去一年中飙升超过 300%</p>

辉瑞的合作伙伴三生制药将通过股票出售筹集 4 亿美元